Suppr超能文献

使用纠错测序技术检测大鼠肝脏样本中的体内诱变性。

Detection of in vivo mutagenicity in rat liver samples using error-corrected sequencing techniques.

作者信息

Izawa Kazuki, Tsuda Masataka, Suzuki Takayoshi, Honma Masamitsu, Sugiyama Kei-Ichi

机构信息

Division of Genetics and Mutagenesis, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-9501, Japan.

Division of General Affairs, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-9501, Japan.

出版信息

Genes Environ. 2023 Nov 22;45(1):30. doi: 10.1186/s41021-023-00288-z.

Abstract

BACKGROUND

Mutagenicity, the ability of chemical agents to cause mutations and potentially lead to cancer, is a critical aspect of substance safety assessment for protecting human health and the environment. Metabolic enzymes activate multiple mutagens in living organisms, thus in vivo animal models provide highly important information for evaluating mutagenicity in human. Rats are considered suitable models as they share a similar metabolic pathway with humans for processing toxic chemical and exhibit higher responsiveness to chemical carcinogens than mice. To assess mutagenicity in rats, transgenic rodents (TGRs) are widely used for in vivo gene mutation assays. However, such assays are labor-intensive and could only detect transgene mutations inserted into the genome. Therefore, introducing a technology to directly detect in vivo mutagenicity in rats would be necessary. The next-generation sequencing (NGS) based error-corrected sequencing technique is a promising approach for such purposes.

RESULTS

We investigated the applicability of paired-end and complementary consensus sequencing (PECC-Seq), an error-corrected sequencing technique, for detecting in vivo mutagenicity in the rat liver samples. PECC-Seq allows for the direct detection of ultra-rare somatic mutations in the genomic DNA without being constrained by the genomic locus, tissue, or organism. We tested PECC-Seq feasibility in rats treated with diethylnitrosamine (DEN), a mutagenic compound. Interestingly, the mutation and mutant frequencies between PECC-Seq and the TGR assay displayed a promising correlation. Our results also demonstrated that PECC-Seq could successfully detect the A:T > T:A mutation in rat liver samples, consistent with the TGR assay. Furthermore, we calculated the trinucleotide mutation frequency and proved that PECC-Seq accurately identified the DEN treatment-induced mutational signatures.

CONCLUSIONS

Our study provides the first evidence of using PECC-Seq for in vivo mutagenicity detection in rat liver samples. This approach could provide a valuable alternative to conventional TGR assays as it is labor- and time-efficient and eliminates the need for transgenic rodents. Error-corrected sequencing techniques, such as PECC-Seq, represent promising approaches for enhancing mutagenicity assessment and advancing regulatory science.

摘要

背景

诱变性是指化学物质引起突变并可能导致癌症的能力,是保护人类健康和环境的物质安全性评估的关键方面。代谢酶可激活生物体内的多种诱变剂,因此体内动物模型为评估人类诱变性提供了非常重要的信息。大鼠被认为是合适的模型,因为它们在处理有毒化学物质方面与人类具有相似的代谢途径,并且对化学致癌物的反应比小鼠更高。为了评估大鼠的诱变性,转基因啮齿动物(TGR)被广泛用于体内基因突变检测。然而,此类检测劳动强度大,且只能检测插入基因组的转基因突变。因此,引入一种直接检测大鼠体内诱变性的技术将是必要的。基于下一代测序(NGS)的纠错测序技术是实现此类目的的一种有前景的方法。

结果

我们研究了双端互补一致测序(PECC-Seq)这种纠错测序技术在检测大鼠肝脏样本体内诱变性方面的适用性。PECC-Seq能够直接检测基因组DNA中极其罕见的体细胞突变,而不受基因组位点、组织或生物体的限制。我们测试了PECC-Seq在经诱变化合物二乙基亚硝胺(DEN)处理的大鼠中的可行性。有趣的是,PECC-Seq与TGR检测之间的突变和突变频率显示出有前景的相关性。我们的结果还表明,PECC-Seq能够成功检测大鼠肝脏样本中的A:T>T:A突变,与TGR检测结果一致。此外,我们计算了三核苷酸突变频率,并证明PECC-Seq准确识别了DEN处理诱导的突变特征。

结论

我们的研究首次证明了使用PECC-Seq检测大鼠肝脏样本体内诱变性。这种方法可为传统的TGR检测提供有价值的替代方案,因为它省时省力,且无需转基因啮齿动物。诸如PECC-Seq之类的纠错测序技术是增强诱变性评估和推动监管科学发展的有前景的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de19/10664353/177beb378342/41021_2023_288_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验